Search

Search bills, members, committees and pages...

H.R. 2343

U.S. HouseIn House Committee

Summary

H.R. 2343, the John W. Walsh Alpha-1 Home Infusion Act of 2025, was introduced in the House on Mar 25, 2025 by Rep. Maria Salazar (R) with 55 co-sponsors. It was referred to Energy And Commerce, and last saw action on Mar 25, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


Record

Text

H.R. 2343 has 55 co-sponsors.

hb2343/introduced-in-house.txt
119 HR 2343 IH: John W. Walsh Alpha-1 Home Infusion Act of 2025
U.S. House of Representatives
2025-03-25
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I 119th CONGRESS 1st Session H. R. 2343 IN THE HOUSE OF REPRESENTATIVES March 25, 2025 Ms. Salazar (for herself, Ms. Pingree , Mr. Smith of New Jersey , Mr. Johnson of Georgia , Mr. Owens , Ms. Norton , Mrs. Kim , Mr. Rouzer , and Mr. Tonko ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL
To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes.
1.
Short title
This Act may be cited as the John W. Walsh Alpha-1 Home Infusion Act of 2025 .
2.
Medicare coverage of Alpha-1 Antitrypsin Disorder treatment
(a)
In general
Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended—
(1)
in subsection (s)(2)—
(A)
by striking and at the end of subparagraph (II);
(B)
by inserting and at the end of subparagraph (JJ); and
(C)
by inserting at the end the following new subparagraph:
(KK)
Alpha-1 Antitrypsin Deficiency Disorder treatment (as defined in subsection (nnn));
; and
(2)
by adding at the end the following new subsection:
(nnn)
Alpha-1 Antitrypsin Deficiency Disorder treatment
(1)
The term Alpha-1 Antitrypsin Deficiency Disorder treatment means augmentation therapy (as defined in paragraph (2)(C)) furnished by qualified home infusion therapy suppliers (as defined in paragraph (2)(D)) which are furnished in the individual’s home (as defined in paragraph (2)(B)) to an individual—
(A)
who is under the care of an applicable provider;
(B)
who is enrolled under both parts A and B of this title, and is not enrolled in an MA plan under part C of such title; and
(C)
who requires augmentation therapy (as defined in paragraph (2)(C)).
(2)
For purposes of this subsection:
(A)
The term applicable provider means—
(i)
a physician;
(ii)
a nurse practitioner; and
(iii)
a physician assistant.
(B)
The term home means a place of residence used as the home of an individual (as defined for purposes of subsection (n)).
(C)
The term augmentation therapy means an Alpha-1 Proteinase Inhibitor indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha-1 Antitrypsin.
(D)
The term qualified home infusion therapy supplier has the meaning given such term in subsection (iii)(3)(D)(i).
.
(b)
Payment for intravenous administration kits and nursing services for Alpha-1 Antitrypsin Deficiency Disorder treatment
Section 1834 of the Social Security Act ( 42 U.S.C. 1395m ) is amended by adding at the end the following new subsection:
(aa)
Payment for intravenous administration kits and nursing services for Alpha-1 Antitrypsin Deficiency Disorder treatment
The Secretary shall implement a payment system under which payment is made under this title to a qualified home infusion therapy supplier (as defined in section 1861(nnn)(3)(D)) for intravenous administration kits and nursing services for up to 2 hours of care by a qualified home infusion therapy supplier in coordination with the furnishing of augmentation therapy (as defined in section 1861(nnn)(2)(C)).
.
(c)
Conforming amendments
(1)
Payment reference
Section 1833(a)(1) of the Social Security Act ( 42 U.S.C. 1395l(a)(1) ) is amended—
(A)
by striking and before (HH) ; and
(B)
by inserting before the semicolon at the end the following: , and (II) with respect to intravenous administration kits and nursing services described in section 1834(aa) for Alpha-1 Antitrypsin Disorder treatment (as defined in subsection (nnn)(1)), the amount paid for such kits and services shall be an amount equal to 80 percent of the lesser of the actual charge for the services or the amount determined under section 1834(aa) .
(2)
Direct payment
The first sentence of section 1842(b)(6) of the Social Security Act ( 42 U.S.C. 1395u(b)(6) ) is amended—
(A)
by striking and before (J) ; and
(B)
by inserting before the period at the end the following: , and (K) in the case of intravenous administration kits and nursing services described in section 1834(aa), payment shall be made to the qualified home infusion therapy supplier (as defined in section 1861(nnn)(2)(D)) .
(3)
Exclusion from home health services
Section 1861(m) of the Social Security Act ( 42 U.S.C. 1395x(m) ) is amended, in the first sentence, by inserting the following before the period at the end: and intravenous administration kits and nursing services described in section 1834(aa) for Alpha-1 Antitrypsin Deficiency Disorder treatment (as defined in subsection (nnn)(1)) .
(d)
Effective date
The amendments made by this section shall apply to items and services furnished on or after January 1, 2027.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-03-25
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in House Mar 25, 2025

hb2343/introduced-in-house.md

Shown Here:
Introduced in House (03/25/2025)

John W. Walsh Alpha-1 Home Infusion Act of 2025

This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.

Sponsors

Rep. Maria Salazar (R) sponsors H.R. 2343, and 55 members have co-sponsored it, 8 of them from the day it was introduced.

Committees

H.R. 2343 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means
Ways and Means
Referred To · Mar 25, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Mar 25, 2025 · 1,636 Bills

Actions

H.R. 2343 has taken 2 actions since Mar 25, 2025.

ChamberAction
Mar 25, 2025
House
Introduced in House
Mar 25, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 2343 has not gone to a roll call.

Titles

H.R. 2343 goes by 3 titles, 1 of them short titles.

  • John W. Walsh Alpha-1 Home Infusion Act of 2025 — Display Title
  • John W. Walsh Alpha-1 Home Infusion Act of 2025 — Short Title(s) as Introduced
  • To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes. — Official Title as Introduced

Lobbying

2 clients hired 2 firms and 8 registered lobbyists who named H.R. 2343 in 10 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Immigration, Budget/Appropriations, Tariff (miscellaneous tariff bills).

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
GRIFOLS SHARED SERVICES NORTH AMERICA INCDistrict of Columbia16
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.Biopharmaceutical companyDistrict of Columbia14$320K

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2026 first_quarter$480K1st Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 fourth_quarter$470K4th Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 third_quarter$450K3rd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 second_quarter$390K2nd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2026 second_quarter$370K2nd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA INCGRIFOLS SHARED SERVICES NORTH AMERICA, INC.2025 first_quarter$360K1st Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)2025 fourth_quarter$80K4th Quarter - Termina…
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)2025 third_quarter$80K3rd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)2025 second_quarter$80K2nd Quarter - Report
GRIFOLS SHARED SERVICES NORTH AMERICA, INC.HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)2025 first_quarter$80K1st Quarter - Report

Classification

The Congressional Research Service files H.R. 2343 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 2343’s is Health.

hr2343/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 2343, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 54 (Tuesday, March 25, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. SALAZAR:H.R. 2343.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 18[Page H1274]

Source: congress.gov · legiscan.com